Details for Patent: 9,006,289

Which drugs does patent 9,006,289 protect, and when does it expire?

Patent 9,006,289 protects LEVOTHYROXINE SODIUM and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 9,006,289

Title:	Levothyroxine formulations
Abstract:	A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 1 to 5 milligrams mannitol. The composition may include from 100 to 200 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 40:1. The composition may include about 500 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 10:1.
Inventor(s):	Jiang; Zhi-Qiang (Skokie, IL), Usayapant; Arunya (Mundelein, IL), Monen; George (Woodridge, IL)
Assignee:	Fresenius Kabi USA, LLC (Lake Zurich, IL)
Application Number:	13/597,884
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,006,289
Patent Claim Types: see list of patent claims	Composition;

Drugs Protected by US Patent 9,006,289

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Fresenius Kabi Usa	LEVOTHYROXINE SODIUM	levothyroxine sodium	POWDER;INTRAVENOUS	202231-001	Jun 24, 2011	AP	RX	Yes	Yes			Y
Fresenius Kabi Usa	LEVOTHYROXINE SODIUM	levothyroxine sodium	POWDER;INTRAVENOUS	202231-002	Jun 24, 2011	AP	RX	Yes	Yes			Y
Fresenius Kabi Usa	LEVOTHYROXINE SODIUM	levothyroxine sodium	POWDER;INTRAVENOUS	202231-003	Jun 24, 2011	AP	RX	Yes	Yes			Y

International Family Members for US Patent 9,006,289

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2750664
World Intellectual Property Organization (WIPO)	2013033194